Home
Explore NIH Technologies
Explore work by over 1,500 NIH researchers | Available for Licensing & Collaboration
News
Company Overview: AUTM is the nonprofit leader in efforts to educate, promote and inspire professionals – throughout their careers – to support the development of academic research that changes the world. AUTM’s community is comprised of more than 3,000 members who work in more than 800 universities
Age-related macular degeneration (AMD) affects approximately 200 million people worldwide and is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late-stage AMD would allow timely medical treatments, lifestyle interventions, more tailored
Ellipsoid zone (EZ) loss has been proposed as evidence of progression of several retinal degenerative diseases, including, but not limited to, retinitis pigmentosa and hydroxychloroquine (HCQ)-induced retinal toxicity. HCQ is a first-line drug used to treat autoimmune diseases such as systemic lupus
Glaucoma is one of the world’s leading causes of irreversible blindness, and currently, no therapies exist to directly protect retinal ganglion cells (RGC) from degradation and loss. NIH inventors have developed a method to treat glaucoma using exosomes derived from bone marrow-derived mesenchymal
Explore Featured Research
Get updates on the latest and most exciting research coming out of NIH...
Explore Featured Products
Novel and interesting products coming to market through NIH inventions and partnerships...